Cancer drug shortage eases slightly; Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise

Taking stock of the drug industry, from the lab to the medicine chest

October 5, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Cancer drug shortage eases slightly, but it's still 'living from paycheck to paycheck' A survey shows 86% of cancer centers lack supplies of a generic chemotherapy drug, putting extra strain on children's cases. By Elizabeth Cooney STAT+ | Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise The unraveling of regenerative medicine firm Histogen provides a glimpse into conversations other biotechs are undoubtedly having behind closed doors. By Jonathan Wosen STAT+ | Was Amgen less than forthcoming about FDA's concerns on its cancer drug? Some analysts believe the company was not fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth. By Ed Silverman Adobe Scientists want to put carbon footprints on drugs. But it's hard to get accurate numbers For pharma and biotech companies, about 90% of emissions come from indirect sources that can be difficult to estimate. By Betsy Ladyzhets

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser